NYSE:NVRONevro Stock Price, Forecast & News

Nevro's stock was trading at $109.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVRO shares have increased by 25.2% and is now trading at $137.51.
View which stocks have been most impacted by COVID-19.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Nevro.

Nevro is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Nevro.

Nevro Corp (NYSE:NVRO) issued its quarterly earnings data on Wednesday, August, 5th. The medical equipment provider reported ($1.21) EPS for the quarter, beating the consensus estimate of ($1.65) by $0.44. Nevro had a negative return on equity of 38.86% and a negative net margin of 27.22%.
View Nevro's earnings history.

10 equities research analysts have issued 12-month target prices for Nevro's shares. Their forecasts range from $100.00 to $165.00. On average, they expect Nevro's stock price to reach $140.40 in the next twelve months. This suggests a possible upside of 2.1% from the stock's current price.
View analysts' price targets for Nevro.

Media headlines about NVRO stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nevro earned a news sentiment score of -2.4 on InfoTrie's scale. They also assigned news headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Nevro.

Some companies that are related to Nevro include Teleflex (TFX), ABIOMED (ABMD), Insulet (PODD), Penumbra (PEN), Novocure (NVCR), Hill-Rom (HRC), Tandem Diabetes Care (TNDM), Globus Medical (GMED), Irhythm Technologies (IRTC), Integra Lifesciences (IART), Haemonetics (HAE), ICU Medical (ICUI), Inari Medical (NARI), Inspire Medical Systems (INSP) and NuVasive (NUVA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Micron Technology (MU), Adobe (ADBE), General Electric (GE), Incyte (INCY), Vertex Pharmaceuticals (VRTX) and ABIOMED (ABMD).

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro's stock is owned by many different institutional and retail investors. Top institutional investors include Jackson Square Partners LLC (3.11%), Victory Capital Management Inc. (1.19%), Goldman Sachs Group Inc. (0.90%), Thrivent Financial for Lutherans (0.76%), Jennison Associates LLC (0.47%) and Principal Financial Group Inc. (0.47%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends for Nevro.

NVRO stock was sold by a variety of institutional investors in the last quarter, including ClariVest Asset Management LLC, Robeco Institutional Asset Management B.V., Mackay Shields LLC, SG Americas Securities LLC, HighTower Advisors LLC, Trexquant Investment LP, Mutual of America Capital Management LLC, and State Board of Administration of Florida Retirement System. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Doug Alleavitch, Michael F Demane, Niamh Louise Pellegrini, and Shawn Mccormick.
View insider buying and selling activity for Nevro.

NVRO stock was bought by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, Thrivent Financial for Lutherans, Jennison Associates LLC, Goldman Sachs Group Inc., Granite Investment Partners LLC, Principal Financial Group Inc., Bellevue Group AG, and Macquarie Group Ltd.. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman, and Kevin C Oboyle.
View insider buying and selling activity for Nevro.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVRO stock can currently be purchased for approximately $137.51.

Nevro has a market capitalization of $4.72 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Nevro employs 804 workers across the globe.

The official website for Nevro is www.nevro.com.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]